MedTrace Logo

4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma

NCT00943449 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2014-01-16

No results posted yet for this study

Summary

The purpose of the study is to determine whether 4SC-201 alone or in combination with Sorafenib is effective and safe in the treatment of hepatocellular carcinoma in patients refractory to Sorafenib monotherapy.

Conditions

Interventions

DRUG

4SC-201

oral administration

DRUG

Sorafenib

oral administration

Sponsors & Collaborators

  • 4SC AG

    lead INDUSTRY

Principal Investigators

  • Michael Bitzer, Prof. MD · Medizinische Universitäts-Klinik Tübingen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-06-30
Completion
2013-09-30

Countries

  • Germany
  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00943449 on ClinicalTrials.gov